A Medline search of research on pharmacotherapy was undertaken , and a previous systematic review on the evidence -based pharmacotherapy of panic disorder was up date d. Selective serotonin reuptake inhibitors remain a first-line pharmacotherapy of panic disorder , with the serotonin noradrenaline reuptake inhibitor venlafaxine also an acceptable early option .
Temporary co-administration of benzodiazepines can be considered .
For patients not responding to first-line agents several pharmacotherapy options are available , but there is a notable paucity of data on the optimal choice
The evidence -based pharmacotherapy of panic disorder continues to evolve .
This paper review s data on first-line pharmacotherapy , evidence for maintenance treatment , and management options for treatment-refractory patients .
A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety
The detailed results are presented of a double-blind controlled trial of phenelzine and placebo in chronic agoraphobic and socially phobic psychiatric out- patients . Forty patients entered the trial and thirty-two of these completed the 8 weeks period of treatment , in which phenelzine or placebo were taken in flexible dosage , 30–90 mg daily . Patients were prospect ively matched in pairs so that clinical response could be assessed in detail . Phenelzine was significantly superior to placebo on a number of measures , particularly for overall assessment ( P<0.01 ) . The treatment differences were not significant after 4 weeks treatment but were so at 8 weeks . The correlates of response and the results of the clinical ratings suggest that phenelzine is not acting as an antidepressant in this population
A Medline search of research on pharmacotherapy was undertaken , and a previous systematic review on the evidence -based pharmacotherapy of panic disorder was up date d. Selective serotonin reuptake inhibitors remain a first-line pharmacotherapy of panic disorder , with the serotonin noradrenaline reuptake inhibitor venlafaxine also an acceptable early option .
Temporary co-administration of benzodiazepines can be considered .
For patients not responding to first-line agents several pharmacotherapy options are available , but there is a notable paucity of data on the optimal choice
The evidence -based pharmacotherapy of panic disorder continues to evolve .
This paper review s data on first-line pharmacotherapy , evidence for maintenance treatment , and management options for treatment-refractory patients .